CONTEXT: Insulin and essential amino acids (EAAs) regulate skeletal muscle protein synthesis, yet their independent effects on mitochondrial protein synthesis (MiPS) and oxidative function remain to be clearly defined. OBJECTIVE: The purpose of this study was to determine the effects of high or low insulin with or without EAAs on MiPS. DESIGN:Thirty participants were randomized to 3 groups of 10 each with each participant studied twice. Study groups comprised (1) low and high insulin, (2) low insulin with and without EAAs, and (3) high insulin with and without EAAs. SETTING: The study was conducted in an in-patient clinical research unit. PARTICIPANTS: Eligible participants were 18 to 45 years old, had a body mass index of <25 kg/m(2), and were free of diseases and medications that might impair mitochondrial function. INTERVENTION: Low (∼ 6 μU/mL) and high (∼ 40 μU/mL) insulin levels were maintained by iv insulin infusion during a somatostatin clamp while maintaining euglycemia (4.7-5.2 mM) and replacing GH and glucagon. The EAA infusion was 5.4% NephrAmine. l-[ring-(13)C6]Phenylalanine was infused, and muscle needle biopsies were performed. MAIN OUTCOMES: Muscle MiPS, oxidative enzymes, and plasma amino acid metabolites were measured. RESULTS:MiPS and oxidative enzyme activities did not differ between low and high insulin (MiPS: 0.07 ± 0.009 vs 0.07 ± 0.006%/h, P = .86) or between EAAs and saline during low insulin (MiPS: 0.05 ± 0.01 vs 0.07 ± 0.01, P = .5). During high insulin, EAAs in comparison with saline increased MiPS (0.1 ± 0.01 vs 0.06 ± 0.01, P < .05) and cytochrome c oxidase activity (P < .05) but not citrate synthase (P = .27). EAA infusion decreased (P < .05) the glucose infusion rates needed to maintain euglycemia during low (∼ 40%) and high insulin (∼ 24%). CONCLUSION: EAAs increased MiPS and oxidative enzyme activity only with high insulin concentrations.
RCT Entities:
CONTEXT: Insulin and essential amino acids (EAAs) regulate skeletal muscle protein synthesis, yet their independent effects on mitochondrial protein synthesis (MiPS) and oxidative function remain to be clearly defined. OBJECTIVE: The purpose of this study was to determine the effects of high or low insulin with or without EAAs on MiPS. DESIGN: Thirty participants were randomized to 3 groups of 10 each with each participant studied twice. Study groups comprised (1) low and high insulin, (2) low insulin with and without EAAs, and (3) high insulin with and without EAAs. SETTING: The study was conducted in an in-patient clinical research unit. PARTICIPANTS: Eligible participants were 18 to 45 years old, had a body mass index of <25 kg/m(2), and were free of diseases and medications that might impair mitochondrial function. INTERVENTION: Low (∼ 6 μU/mL) and high (∼ 40 μU/mL) insulin levels were maintained by iv insulin infusion during a somatostatin clamp while maintaining euglycemia (4.7-5.2 mM) and replacing GH and glucagon. The EAA infusion was 5.4% NephrAmine. l-[ring-(13)C6]Phenylalanine was infused, and muscle needle biopsies were performed. MAIN OUTCOMES: Muscle MiPS, oxidative enzymes, and plasma amino acid metabolites were measured. RESULTS: MiPS and oxidative enzyme activities did not differ between low and high insulin (MiPS: 0.07 ± 0.009 vs 0.07 ± 0.006%/h, P = .86) or between EAAs and saline during low insulin (MiPS: 0.05 ± 0.01 vs 0.07 ± 0.01, P = .5). During high insulin, EAAs in comparison with saline increased MiPS (0.1 ± 0.01 vs 0.06 ± 0.01, P < .05) and cytochrome c oxidase activity (P < .05) but not citrate synthase (P = .27). EAA infusion decreased (P < .05) the glucose infusion rates needed to maintain euglycemia during low (∼ 40%) and high insulin (∼ 24%). CONCLUSION:EAAs increased MiPS and oxidative enzyme activity only with high insulin concentrations.
Authors: Lee D Roberts; Pontus Boström; John F O'Sullivan; Robert T Schinzel; Gregory D Lewis; Andre Dejam; Youn-Kyoung Lee; Melinda J Palma; Sondra Calhoun; Anastasia Georgiadi; Ming-Huei Chen; Vasan S Ramachandran; Martin G Larson; Claude Bouchard; Tuomo Rankinen; Amanda L Souza; Clary B Clish; Thomas J Wang; Jennifer L Estall; Alexander A Soukas; Chad A Cowan; Bruce M Spiegelman; Robert E Gerszten Journal: Cell Metab Date: 2014-01-07 Impact factor: 27.287
Authors: Michael Krebs; Martin Krssak; Elisabeth Bernroider; Christian Anderwald; Attila Brehm; Martin Meyerspeer; Peter Nowotny; Erich Roth; Werner Waldhäusl; Michael Roden Journal: Diabetes Date: 2002-03 Impact factor: 9.461
Authors: Craig S Stump; Kevin R Short; Maureen L Bigelow; Jill M Schimke; K Sreekumaran Nair Journal: Proc Natl Acad Sci U S A Date: 2003-06-13 Impact factor: 11.205
Authors: Matthew M Robinson; Surendra Dasari; Helen Karakelides; H Robert Bergen; K Sreekumaran Nair Journal: Am J Physiol Endocrinol Metab Date: 2016-07-19 Impact factor: 4.310
Authors: Gordon I Smith; Jun Yoshino; Shannon C Kelly; Dominic N Reeds; Adewole Okunade; Bruce W Patterson; Samuel Klein; Bettina Mittendorfer Journal: Cell Rep Date: 2016-10-11 Impact factor: 9.423
Authors: Surendra Dasari; Sean A Newsom; Sarah E Ehrlicher; Harrison D Stierwalt; Matthew M Robinson Journal: Am J Physiol Endocrinol Metab Date: 2018-05-29 Impact factor: 4.310
Authors: Sean A Newsom; Benjamin F Miller; Karyn L Hamilton; Sarah E Ehrlicher; Harrison D Stierwalt; Matthew M Robinson Journal: Am J Physiol Endocrinol Metab Date: 2017-07-11 Impact factor: 4.310
Authors: Lydia-Ann L S Harris; Gordon I Smith; Bruce W Patterson; Raja S Ramaswamy; Adewole L Okunade; Shannon C Kelly; Lane C Porter; Samuel Klein; Jun Yoshino; Bettina Mittendorfer Journal: Diabetes Date: 2017-05-04 Impact factor: 9.461
Authors: Sarah Everman; Christian Meyer; Lee Tran; Nyssa Hoffman; Chad C Carroll; William L Dedmon; Christos S Katsanos Journal: Am J Physiol Endocrinol Metab Date: 2016-08-16 Impact factor: 4.310
Authors: Brian A Irving; Rickey E Carter; Mattias Soop; Audrey Weymiller; Husnain Syed; Helen Karakelides; Sumit Bhagra; Kevin R Short; Laura Tatpati; Rocco Barazzoni; K Sreekumaran Nair Journal: Metabolism Date: 2015-01-22 Impact factor: 8.694
Authors: Gregory N Ruegsegger; Ana L Creo; Tiffany M Cortes; Surendra Dasari; K Sreekumaran Nair Journal: J Clin Invest Date: 2018-08-31 Impact factor: 14.808